CatalYm focuses on targeting GDF-15, a factor associated with immunosuppression in tumors, to improve the effectiveness of existing cancer immunotherapies. Their lead product candidate, CTL-002, is a GDF-15 antibody that is set to enter clinical development in 2020. The company aims to demonstrate the clinical potential of CTL-002 in multiple solid tumor indications, expanding treatment options for cancer patients. CatalYm was founded in 2016 and is based in Martinsried, Germany.